Transition to delta matter from hot, dense nuclear matter within a relativistic mean field formulation of the nonlinear sigma and omega model

An investigation of the transition to delta matter is performed based on a relativistic mean field formulation of the nonlinear sigma and omega model. We demonstrate that in addition to the Delta-meson coupling, the occurrence of the baryon resonance isomer also depends on the nucleon-meson coupling. Our results show that for the favored phenomenological value of m* and K, the Delta isomer exists at baryon density ~ 2–3 p0 if beta=1.31 is adopted. For universal coupling of the nucleon and Delta, the Delta density at baryon density ~ 2–3 p0 and temperature ~ 0.4–0.5 fm-1 is about normal nuclear matter density, which is in accord with a recent experimental finding

Comparative Study of IFN-Based Versus IFN-Free Regimens and Their Efficacy in Treatment of Chronic Hepatitis C Infections

The hepatitis C viral (HCV) infection is a global health burden, WHO estimates 130–150 million people chronically infected with hepatitis C virus worldwide. Additional 3–4 million people become newly infected annually and more than 350,000 people die each year of HCV-related liver diseases. HCV infection exhibits higher genetic diversity with regional variations in genotypic prevalence resulting big challenges on disease management. Introduction of DAAs revolutionised the new era of all oral therapy in treatment of chronic hepatitis C infection and is the regimens of choice in present days. However, IFN-based combination therapy with sofosbuvir has promising efficacy in genotypes 3, 4, 5 or 6 infections compared to genotypes 1 and 2 infections. So, these regimens could be an option in DAAs regimen failure cases. The poor availability of data on recent DAAs (IFN-free) regimens questioned on regular use and cost effectiveness is the another challenge with DAAs regimens. So phase III trials (sofosbuvir and velpatasvir) of recent DAAs with pangenotypic actions and better tolerability in HCV infected patients are the future advances in treatment of chronic hepatitis C. After all those recent combination therapies with better SVR, the combination of pegylated interferon with ribavirin is the only option available where unavailability of other regimens still exists